Pharmacodynamics and pharmacokinetics
Pharmacodynamics
Sertraline serotonin reuptake inhibitor . As a result, the concentration of this neurotransmitter increases, eliminating serotonin deficiency, which is the main cause of depressive conditions.
Does not produce a psychostimulating, sedative or m-anticholinergic effect. Has no affinity for serotonergic , muscarinic , GABA receptors and benzodiazepine receptors , does not inhibit MAO. Does not cause drug dependence and weight gain. There is also no cardiotoxic effect of the drug.
The antidepressant effect of the drug is observed by the end of the second week, and the initial effect is in the first week.
Pharmacokinetics
Absorbed from the gastrointestinal tract completely, but slowly. Cmax in the blood is determined after 5-8 hours. Bioavailability increases with simultaneous food intake. 98% bound to blood proteins. Excreted in breast milk. There is no data on the possibility of penetration through the placental barrier. Metabolized in the liver. Excreted in urine and feces. T 1/2 is 22-36 hours.
Stimulong
Pharmacological properties
The drug, thanks to the synergistic interaction of butaphosphamide and cyanocobalamin, has a tonic effect, regulates metabolism and stimulates regenerative processes, increases the resistance of the animal’s body to diseases of various etiologies, exhaustion and stress caused by transportation and unfavorable living conditions.
Butaphosphan is an organic phosphorus compound that stimulates metabolic processes, smooth muscle and bone formation, and also improves liver function. Unlike inorganic phosphorus, butaphosphamide does not accumulate in the body, due to which the drug is characterized by a low degree of toxicity. Butaphosphan regulates cortisol levels.
Cyanocobalamin (vitamin B12) stimulates hematopoiesis, restores the normal level of suppressor lymphocytes, participates in the formation of creatine, fat metabolism, promotes the formation of glycogen, mobilizes energy reserves, is necessary for the formation of deoxyribose, stimulates the biosynthesis of DNA and methionine, normalizes the process of absorption of substances supplied with food .
Doses and method of administration
The drug is administered to animals intramuscularly, subcutaneously, and to poultry orally once a day in the following doses: (ml per animal) for acute diseases: - horses, cattle 10.0-25.0 ml; - calves, foals 5.0-12.0 ml; - sheep, goats 2.5-8.0 ml; — lambs, kids 1.5-2.5 ml; - pigs 2.5-10.0 ml; — suckling piglets 1.0-2.5 ml; — dogs 0.5-5.0 ml; - cats and fur-bearing animals 0.5-2.5 ml. For chickens, 1.0-1.5 ml per 1 liter of drinking water; for laying hens 2.0-3.0 ml per 1 liter of drinking water. The duration of use of the drug is 4-5 days. For chronic diseases, the drug is administered at half the dose indicated above. If necessary, repeat the course after 5-14 days.
Contraindications
No contraindications have been established.
Restrictions on product use:
- slaughter of animals for meat and use of milk for food purposes after using the drug is permitted without restrictions
Storage conditions and periods:
The drug is stored in the manufacturer's packaging in a place protected from light and moisture, at a temperature from plus 20 C to plus 25 0 C. The drug is stored separately from food and feed, out of the reach of children.
Primary packaging:
— glass bottles of 100 ml
Indications for use
- depressive states;
- recurrent (repeating) depression ;
- prevention of episodes of depression;
- panic disorders;
- social phobia;
- state of anxiety and depression at the same time;
- obsessive-compulsive disorder;
- stress disorder after trauma.
Contraindications
- recurrent attacks of epilepsy ;
- taking MAO inhibitors ;
- age up to 18 years, except for patients with obsessive-compulsive disorder;
- hypersensitivity to the drug;
- pregnancy and breastfeeding.
Some caution should be exercised when prescribing Stimuloton for manic states , mental retardation, liver and kidney failure .
Special instructions for the use of the drug Stimuloton
Electroconvulsive therapy There are no data regarding the risks or benefits of electroconvulsive therapy and sertraline. Activation of mania and hypomania Like other antidepressants, the drug can cause mania or hypomania (up to 0.4% of patients). Suicide Patients with depression belong to a risk group for suicide attempts. From the start of treatment until the development of a pronounced clinical effect, such patients should be under close medical supervision. Use in children and adolescents under 18 years of age Stimuloton should not be used to treat children and adolescents under 18 years of age, with the exception of patients with OCD. If the drug is prescribed for clinical indications, it is necessary to monitor the patient for timely detection of suicide attempts. Epileptic seizures A direct connection between epileptic seizures and the use of sertraline has not been established. The drug should not be prescribed to patients with unstable epilepsy. If attacks occur, sertraline should be discontinued. Hepatic impairment Sertraline metabolism occurs primarily in the liver. Sertraline should be prescribed with caution to patients with impaired liver function. It is possible to reduce the dose or increase the interval between taking the drug. Renal failure Patients with impaired renal function do not need special dosage selection. Pregnancy and lactation Due to the lack of adequate clinical data during pregnancy, sertraline can be prescribed only when the benefit of the drug justifies the possible risk to the fetus or child. Sertraline is excreted into milk, so it is not recommended to use it during breastfeeding. Effect on the ability to drive vehicles and potentially dangerous mechanisms Sertraline monotherapy does not affect the psychomotor performance of patients. Clinical studies did not reveal any undesirable effects on the ability to drive vehicles or use other machinery.
Side effects of Stimuloton
All side effects are rare:
- drowsiness, dizziness , insomnia , headache, tremor , hallucinations , irritability , restlessness syndrome, agitation;
- dry mouth, stomach cramps, loss of appetite, flatulence , abdominal pain, nausea;
- heartbeat;
- weight loss;
- nosebleeds;
- blurred vision;
- dysmenorrhea , decreased potency, delayed ejaculation;
- skin hyperemia , rash, itching;
- increased sweating;
- increased AST and ALT;
- withdrawal syndrome.
Instructions for use of Stimuloton (Method and dosage)
The tablets are taken orally, 1 time per day. The time of admission does not matter (morning or evening).
Treatment of depression and obsessive-compulsive disorder: 50 mg for adults.
For panic disorders, treatment begins with 25 mg, after 7 days the dose is increased to 50 mg. In these conditions, if necessary, the dose is increased by 25–50 mg once a week to the MS dose of 200 mg. The effect of treatment occurs within a week; for a full and lasting antidepressant effect, it takes from 2 weeks to 1 month. The minimum effective dose is prescribed as maintenance therapy.
Children from 13 to 18 years old with obsessive-compulsive disorder - 50 mg. For children 6 to 12 years of age with this condition, 25 mg is recommended, increasing to 50 mg every other week. In the future, it is allowed to increase the dose by 50 mg every week up to an MS dose of 200 mg. Since children have less body weight, the possibility of overdose must be taken into account. For maintenance therapy, the minimum effective doses are selected.
Instructions for use of Stimuloton contain information on the dosage of the drug in certain groups: elderly patients and patients with impaired renal function - the dose is not adjusted, severe liver dysfunction - the dose is reduced.
Stimuloton tablet p/o 100 mg per bl. in pack No. 14x2
Name
Stimuloton.
Description
Film-coated tablets, white or almost white, oval, biconvex, engraved “E271” on one side and scored on the other, odorless.
Main active ingredient
Sertraline
Release form
Film-coated tablets, white or almost white, oval, biconvex, engraved “E271” on one side and scored on the other, odorless. 1 tab. sertraline hydrochloride 55.95 mg, which corresponds to the content of sertraline 50 mg Excipients: magnesium stearate - 2 mg, hyprolose (hydroxypropylcellulose) - 6.05 mg, sodium carboxymethyl starch (type A) - 20 mg, calcium hydrogen phosphate dihydrate - 24 mg, microcrystalline cellulose - 45 mg . Shell composition: hypromellose - 2.9 mg, macrogol 6000 - 0.8 mg, titanium dioxide (CI77891 EEC 171) - 1.3 mg. 10 pieces. - blisters (1) - cardboard packs. 10 pieces. - blisters (2) - cardboard packs. 10 pieces. - blisters (3) - cardboard packs. Film-coated tablets, white or almost white, oval, biconvex, engraved “E272” on one side and scored on the other, odorless. 1 tab. sertraline hydrochloride 111.9 mg, which corresponds to the content of sertraline 100 mg Excipients: magnesium stearate - 4 mg, hyprolose (hydroxypropylcellulose) - 12.1 mg, sodium carboxymethyl starch (type A) - 40 mg, calcium hydrogen phosphate dihydrate - 48 mg, microcrystalline cellulose - 90 mg . Shell composition: hypromellose - 5.8 mg, macrogol 6000 - 1.6 mg, titanium dioxide (CI77891 EEC 171) - 2.6 mg. 14 pcs. - blisters (1) - cardboard packs. 14 pcs. - blisters (2) - cardboard packs.
Dosage
50 mg per bl. in pack №10x3
special instructions
There are no data on the possible risks and benefits of simultaneous use of electroconvulsive therapy and Stimuloton. Like other antidepressants, Stimuloton® in some cases (approximately 0.4%) can cause mania or hypomania. Suicidal thoughts and attempts are often associated with depression; they are possible at any time before the onset of remission. Therefore, at the beginning of the course of treatment, until the optimal clinical effect develops, patients need careful medical supervision. In clinical trials of Stimuloton, epileptic seizures were observed in 0.08% of patients with depression (approximately 3/4000) and in 0.2% of patients with obsessive-compulsive disorder (4/1800). A strict connection between epileptic seizures and the use of Stimuloton has not been established. There is no data on the treatment of patients with epilepsy with Stimuloton. The drug should not be prescribed to patients with unstable epilepsy, and patients who do not have seizures should be monitored regularly. If seizures occur, Stimuloton® must be discontinued. Sertraline is metabolized mainly in the liver, so caution is required when prescribing Stimuloton to patients with liver disease. Use in pediatrics The use of Stimuloton is contraindicated for the treatment of children and adolescents under 18 years of age, with the exception of patients with obsessive-compulsive disorder. Increases in the likelihood of suicide and suicidal ideation, as well as hostility (mainly aggression, defiance and anger), have been observed more frequently in clinical trials among children and adolescents receiving antidepressants compared with groups receiving placebo. If the drug is prescribed for clinical indications, the patient should be monitored to identify suicidal symptoms. In addition, there are no long-term safety data in children and adolescents regarding growth, maturation, and cognitive and behavioral development. Effect on the ability to drive vehicles and operate machinery. The results of clinical studies have shown that monotherapy with Stimuloton does not affect indicators of psychomotor function. However, since other drugs used for similar indications may adversely affect psychomotor reactions, the ability to drive vehicles and machines should be determined individually depending on the patient's response to treatment and the use of concomitant therapy.
pharmachologic effect
Antidepressant. Selective serotonin reuptake inhibitor. It has a weak effect on the reuptake of norepinephrine and dopamine. In therapeutic doses, sertraline also blocks the uptake of serotonin by human blood platelets. Does not have a stimulating, sedative or anticholinergic effect. Sertraline has no affinity for m-cholinergic, serotonin, dopamine, histamine, adrenergic, GABA and benzodiazepine receptors. When using Stimuloton, there is no increase in body weight. The drug does not cause mental or physical drug dependence. The antidepressant effect is observed by the end of the second week of regular use of the drug, while the maximum effect is achieved only after 6 weeks.
Pharmacokinetics
Absorption After oral administration, it is absorbed from the gastrointestinal tract slowly, but almost completely. Cmax is reached after 4.5-8.4 hours. When taking the drug simultaneously with food, its bioavailability increases by 25%, Cmax is achieved faster. Distribution With a single daily dose of the drug, Css is usually achieved within a week. Plasma protein binding is 98%. Vd - more than 20 l/kg. Sertraline is excreted in breast milk. There is no data on its ability to penetrate the placental barrier. Metabolism Sertraline undergoes extensive first-pass metabolism through the liver, undergoing N-demethylation. Its main metabolite, N-desmethylsertraline, is less active than sertraline. Elimination T1/2 is 22-36 hours and does not depend on the age and gender of patients. T1/2 of N-desmethylsertraline is 62-104 hours. It is excreted in the form of metabolites in urine and feces in equal amounts, 0.2% of sertraline is excreted in the urine unchanged. Pharmacokinetics in special clinical cases T1/2 and AUC of sertraline increase with impaired liver function. Pharmacokinetic studies with the administration of the drug in a single dose revealed an increase in T1/2 and AUC of sertraline in patients with liver cirrhosis. Regardless of the severity of renal failure, the pharmacokinetics of sertraline does not change with its continuous use. Sertraline is not eliminated by hemodialysis.
Indications for use
- depression of various etiologies, incl. accompanied by feelings of anxiety (treatment and prevention); — obsessive-compulsive disorders, incl. in children over 6 years old; - panic disorders (with or without agoraphobia); - post-traumatic stress disorder.
Directions for use and doses
The drug is prescribed orally, 1 time/day (morning or evening). For adults with depression and obsessive-compulsive disorders, the drug is prescribed at a dose of 50 mg 1 time / day. For panic disorders and post-traumatic stress disorders, to reduce the frequency and severity of side effects, it is recommended to start treatment with a dose of 25 mg 1 time / day and after a week increase it to 50 mg 1 time / day. If the therapeutic response is unsatisfactory and is well tolerated, the daily dose can be increased by 50 mg over several weeks to a maximum daily dose of 200 mg. The therapeutic effect is usually achieved within 7 days. However, for the full manifestation of the antidepressant effect, regular use of the drug is required for 2-4 weeks. In obsessive-compulsive disorder, the therapeutic effect develops even more slowly. For maintenance therapy, the minimum effective dose should be prescribed. For obsessive-compulsive disorders in children aged 13 to 18 years, the drug is prescribed at an initial dose of 50 mg 1 time / day. For children aged 6 to 12 years, the drug is prescribed at an initial dose of 25 mg 1 time / day; after a week, the daily dose can be increased to 50 mg. If the therapeutic response is unsatisfactory, the dose can then be increased weekly by 50 mg/day to a maximum daily dose of 200 mg. To avoid overdose, when increasing the dose to more than 50 mg/day, it should be taken into account that the body weight of children is less than that of adults. For long-term maintenance therapy, the drug should be prescribed in the minimum effective dose. In elderly patients, no dose adjustment is required. In patients with severe liver dysfunction, the dose of the drug should be reduced or the intervals between doses increased. In patients with impaired renal function, no special dose selection is required.
Use during pregnancy and lactation
There are no controlled results of the safety of using Stimuloton in pregnant women, therefore its use during pregnancy is contraindicated. Women of reproductive age who are to be prescribed Stimuloton should be advised to use effective contraception. Sertraline is excreted in breast milk. There is no reliable data on the safety of its use during lactation. If it is necessary to prescribe Stimuloton during lactation, breastfeeding should be stopped.
Precautionary measures
The drug should be prescribed with caution in case of organic diseases of the brain (including mental retardation), manic states, epilepsy, liver and/or kidney failure, weight loss, as well as children over 6 years of age with OCD.
Interaction with other drugs
When using Stimuloton simultaneously with MAO inhibitors, incl. with selegiline and the reversible MAO inhibitor moclobemide, severe complications are observed. Serotonin syndrome may develop. Several cases of death have been reported with the combination of other antidepressants and MAO inhibitors, as well as with the isolated administration of MAO inhibitors, started immediately after discontinuation of other antidepressants. When a selective serotonin reuptake blocker and an MAO inhibitor were combined, hyperthermia, rigidity, myoclonus, autonomic instability (sometimes with rapid changes in respiratory and circulatory function), mental status changes (for example, confusion, irritability, sometimes with extreme agitation, which could lead to delirium or coma). Therefore, the use of Stimuloton in combination with MAO inhibitors or within 14 days after discontinuation of a MAO inhibitor, as well as less than 1 day after discontinuation of a reversible MAO inhibitor, is contraindicated. Similarly, after discontinuation of Stimuloton, at least 14 days must pass before starting the use of an irreversible MAO inhibitor. In studies in healthy volunteers, with daily intake of Stimuloton at a dose of 200 mg/day, there was no increase in the effect of ethanol, carbamazepine, haloperidol or phenytoin on cognitive functions and psychomotor reactions. However, while taking sertraline, drugs that affect the central nervous system should be used with extreme caution; the use of ethanol during treatment should be avoided. Sertraline is highly bound to plasma proteins and the potential for interaction with other plasma protein-bound drugs (eg diazepam, tolbutamide and warfarin) must be considered. With simultaneous use of Stimuloton with cimetidine, the clearance of sertraline is significantly reduced. With the simultaneous use of Stimuloton with coumarin derivatives, a significant increase in prothrombin time is observed (in such cases, it is recommended to monitor the prothrombin time at the beginning of treatment with sertraline and after its discontinuation). During long-term therapy with Stimuloton at a dose of 50 mg/day, the use of drugs metabolized with the participation of the CYP2D6 isoenzyme is accompanied by an increase in their concentrations in the blood plasma. In vivo drug interaction studies have shown that long-term administration of sertraline at a dose of 200 mg/day does not affect the endogenous beta-hydroxylation of cortisol mediated by CYP3A3/4 isoenzymes or the metabolism of carbamazepine or terfenadine. Long-term administration of sertraline at a dose of 200 mg/day does not affect the concentrations of tolbutamide, phenytoin and warfarin in blood plasma. This means that sertraline does not inhibit CYP2C9 activity to a clinically significant extent. Long-term administration of sertraline at a dose of 200 mg/day does not affect the concentration of diazepam in the blood plasma, and therefore clinically significant inhibition of the activity of the CYP2C19 isoenzyme should also be excluded. In vitro studies have shown that sertraline has no or minimal inhibitory effect on CYP1A2. With simultaneous use of Stimuloton and lithium preparations, the pharmacokinetics of the latter does not change. However, with this combination, tremor is observed more often. Just as when prescribing other selective serotonin reuptake inhibitors, increased caution is required when combining Stimuloton with drugs that affect serotonergic transmission (including lithium drugs). The time required for complete elimination of the active substance from the body before transferring a patient from one selective serotonin reuptake inhibitor to another has not been determined. Therefore, such a transition should be made with extreme caution. Particular caution is required when other serotonergic substances (e.g. tryptophan or fenfluramine) and sertraline are used concomitantly. Such combinations should be avoided whenever possible. In clinical studies, only a slight inducing effect of sertraline on liver enzymes was found. With simultaneous use of Stimuloton at a dose of 200 mg/day and phenazone, sertraline caused a small (5%) but significant decrease in T1/2 of phenazone. This small decrease in T1/2 of phenazone was due to a clinically insignificant change in liver metabolism. When used together, sertraline does not change the beta-blocking effect of atenolol. When combining Stimuloton at a dose of 200 mg/day with glibenclamide and digoxin, no drug interactions were detected.
Contraindications
- simultaneous use of MAO inhibitors and a period of 14 days after their discontinuation; - unstable epilepsy; - age under 18 years (due to lack of sufficient clinical experience), with the exception of patients with obsessive-compulsive disorders; - pregnancy; - lactation period (breastfeeding); - hypersensitivity to the components of the drug.
Compound
1 tab. sertraline hydrochloride 55.95 mg, which corresponds to the content of sertraline 50 mg Excipients: magnesium stearate - 2 mg, hyprolose (hydroxypropylcellulose) - 6.05 mg, sodium carboxymethyl starch (type A) - 20 mg, calcium hydrogen phosphate dihydrate - 24 mg, microcrystalline cellulose - 45 mg . Shell composition: hypromellose - 2.9 mg, macrogol 6000 - 0.8 mg, titanium dioxide (CI77891 EEC 171) - 1.3 mg. 10 pieces. - blisters (3) - cardboard packs.
Overdose
Even when sertraline was prescribed in high doses, no severe symptoms were detected. However, administration of sertraline in high doses simultaneously with other drugs or ethanol can lead to severe poisoning. Symptoms: serotonin syndrome with nausea, vomiting, drowsiness, tachycardia, agitation, dizziness, psychomotor agitation, diarrhea, increased sweating, myoclonus and hyperreflexia. Treatment: There are no specific antidotes. Intensive supportive care and constant monitoring of vital organ functions are required. Inducing vomiting is not recommended. The administration of activated carbon may be more effective than gastric lavage. The airway must be maintained. Sertraline has a large Vd, and therefore increased diuresis, dialysis, hemoperfusion or blood transfusion may be ineffective.
Side effect
From the central nervous system and peripheral nervous system: rarely - drowsiness, fatigue, dizziness, headache, tremor, insomnia, irritability, akathisia, hypomania, mania. As with treatment with other antidepressants, reactions may occur that are difficult to differentiate from symptoms of the underlying disease, including. paresthesia, hypoesthesia, depression, hallucinations, agitation, aggressiveness, agitation, anxiety, psychosis. From the digestive system: dry mouth, decreased appetite or increased appetite (possibly due to the elimination of depression); rarely - anorexia, cramps in the stomach, abdomen, flatulence or pain, unstable stools, diarrhea, dyspepsia, nausea, vomiting. From the cardiovascular system: rarely - palpitations. Metabolism: weight loss. From the hematopoietic system: bleeding (including nosebleeds). From the senses: rarely - visual disturbances (including blurred vision). From the reproductive system: rarely - dysmenorrhea, sexual dysfunction (delayed ejaculation, decreased potency and/or libido, anorgasmia). Dermatological reactions: rarely - skin hyperemia or “flushes” of blood to the face, increased sweating. From the laboratory parameters: in some cases (0.8%) - an asymptomatic increase in AST and ALT (these changes were observed during the first 9 weeks of taking the drug and stopped immediately after its discontinuation); There are reports of reversible hyponatremia (presumably this phenomenon is associated with the syndrome of insufficient ADH secretion, since it was observed mainly in elderly patients receiving concomitant diuretics or other drugs). Other: rarely - allergic reactions, yawning; in some cases, stopping the drug causes withdrawal syndrome. Sometimes (a causal relationship with the drug has not been reliably established) - motor disorders (extrapyramidal symptoms and gait disturbances), convulsions, menstrual irregularities, hyperprolactinemia, galactorrhea, skin rash (rarely - erythema multiforme), itching. In most cases, movement disorders were observed in patients taking concomitant antipsychotic drugs (neuroleptics), as well as in those with a long history of movement disorders.
Storage conditions
The drug should be stored out of the reach of children at a temperature not exceeding 25°C.
Buy Stimuloton tablet p/o 100 mg in bl. in pack No. 14x2 in the pharmacy
Price for Stimuloton tablet p/o 100 mg per bl. in pack No. 14x2
Instructions for use for Stimuloton tablet p/o 100 mg per bl. in pack No. 14x2
Overdose
Stimuloton, even in large doses, does not cause severe overdose symptoms. But when it is prescribed with psychotropic drugs, cases of poisoning are observed. Overdose is manifested by the appearance of serotonin syndrome :
- movement disorders (muscle twitching, tremors , bruxism , ataxia );
- autonomic disorders (chills, profuse sweating, nausea, abdominal pain, stool upset, tachycardia , blood pressure fluctuations);
- mental disorders ( disorientation , agitation, hypomania , confusion ).
There are no antidotes. Intensive therapy and monitoring of cardiac activity and respiratory function are carried out. Gastric lavage is not very effective; sorbents .
Interaction
Drugs that affect the central nervous system ( Carbamazepine , Haloperidol , Phenytoin ) should be used with caution. You must abstain from drinking alcohol.
Prescribing monoamine oxidase inhibitors with simultaneous administration of sertraline leads to significant complications in the form of the development of serotonin syndrome . After discontinuation of the drug, treatment with MAO inhibitors begins only after 2 weeks.
Since the active substance binds to blood proteins, this pharmacokinetic feature must be taken into account when prescribing Diazepam , Warfarin and other drugs that also bind to proteins.
Cimetidine reduces the clearance of sertraline.
Tremor is observed when used in combination with lithium , and coumarin increase PT (prothrombin time). Concomitant use with other serotonergic drugs ( Tryptophan , Fenfluramine ) should be avoided.
Drug interactions Stimuloton
MAO inhibitors According to available data, the combined use of sertraline with MAO inhibitors, including selegiline and the reversible inhibitor moclobemide, leads to serious consequences. When these drugs were combined, hyperthermia, muscle rigidity, myoclonus, lability of the autonomic nervous system, and mental status changes, including irritability, agitation, which may progress to delirium or coma, were noted. Therefore, sertraline should never be prescribed together with MAO inhibitors or within 14 days after their discontinuation, or less than 1 day after discontinuation of a reversible MAO inhibitor. Similarly, after discontinuation of sertraline therapy, at least 14 days must elapse before starting the use of a reversible MAO inhibitor. CNS depressants and alcohol Daily use of sertraline 200 mg/day does not enhance the effect of alcohol, carbamazepine, haloperidol or phenytoin on cognitive function and psychomotor activity. Protein-Bound Drugs Since sertraline is bound to plasma proteins, the possibility of interaction with other protein-bound drugs must be considered. Cimetidine Concomitant use significantly reduces the clearance of sertraline, however, the clinical significance of this has not been established. Coumarin derivatives Coumarin derivatives significantly increase prothrombin time, therefore it is necessary to monitor prothrombin time at the beginning of treatment and after its discontinuation. Drugs metabolized by the cytochrome P450 isoenzyme Long-term treatment with sertraline at a dose of 50 mg/day is accompanied by an increase in the concentration of despramine (a compound used to assess the activity of the 2D6 isoenzyme of cytochrome P450) in the blood plasma. Lithium A study in healthy volunteers showed that pharmacokinetics do not change significantly when lithium is administered concomitantly with sertraline. However, compared with the placebo group, the incidence of tremor was higher, suggesting a possible pharmacodynamic interaction. Serotonergic agents The length of the washout period required before switching a patient from one selective serotonin reuptake inhibitor to another has not yet been determined and requires extreme caution. It is advisable to avoid simultaneous administration of tryptophan or fenfluramine and sertraline. Induction of microsomal enzymes Studies have revealed a slight inducing effect of sertraline on liver enzymes. Atenolol When used concomitantly, sertraline does not change the β-blocking effect of atenolol. Glibenclamide and digoxin No interactions have been identified.
Analogs
Level 4 ATC code matches:
Actaparoxetine
Plizil
Fluxen
Paroxin
Surlift
Asentra
Elycea
Fluoxetine
Lenuksin
Escitalopram
Adepress
Selectra
Citalopram
Cipramil
Zoloft
Paroxetine
Prozac
Paxil
Rexetine
Fevarin
Aleval , Asentra , Zoloft , Serenata , Sirlift , Thorin , Deprefault , Deprefault , Sertraline hydrochloride .
Reviews about Stimuloton
Reviews about Stimuloton on forums indicate the effectiveness of the drug and the absence of addiction to it when prescribed correctly.
According to patients who took the drug, tension and anxiety gradually go away, there is no excitement or worry about any reason:
“Stimuloton helps! He brought me back to life."
“I’ve been taking Stimuloton for 5 years in a small dose, everything is fine,” “...it started helping me on the second day—the panic attacks stopped.”
“I took the pills for about 6 months, my psychological state improved significantly, I didn’t feel any addiction...”, “...I didn’t feel any addiction either.”
Negative reviews, although there are few of them, are associated with the appearance of side effects, among which the most prominent ones are the appearance of insomnia, fatigue, sweating, apathy and loss of appetite.
Antidepressant Stimuloton - reviews
Khaleesi
https://irecommend.ru/content/esli-u-vas-realnye-problemy-prosto-poprobuite-etot-preparat-moi-opyt-priema-vnutri
I took exactly 50 mg per day. I was immediately prescribed this dosage - and when I “came off” from this drug, I first reduced the dose by half... By the way, the active ingredient in this drug is sertraline, it can be bought cheaper in its pure form in a pharmacy if you have a prescription from a doctor. Stimuton itself is quite expensive - 900 rubles for a package of 30 pieces.
Was there any effect? Definitely, yes - I no longer wanted to worry at least to some extent about my physical condition, I became calmer in this regard, I stopped worrying about how much I correspond to generally accepted standards. If you suffer from panic disorders or obsessive-compulsive disorders, you should definitely try this drug! No therapy can compare with the effect of drugs; you simply become a different person. Even my relationships with my family, with the people around me, are improving, I have become much more contactable, more adequate, and more sociable.
Stimuloton is considered an antidepressant, so it is usually prescribed for a long time - from three months or more. I took it for about 4 months, and if my mental state worsens, I will most likely be given a prescription again. Such long-term treatment, in principle, is often practiced when taking antidepressants, there is nothing wrong with that.
LIKUSHA13
https://irecommend.ru/content/effektivnyi-preparat-19
I have suffered from agoraphobia and panic attacks for many years. Therefore, you have to periodically take antidepressants in courses 2 times a year. They help me cope with my not very good condition and live fully.
I have already tried many antidepressants to find the best one for me. One of them was Stimuloton.
This is a new generation antidepressant. It is not addictive and there is no withdrawal syndrome. It is necessary to take Stimuloton in full course. A one-time dose will not do any good. The drug must accumulate in the body, only then will it begin to act.
The effect of taking the drug is good. A surge of vitality appeared, fears went away and panic attacks decreased.
One drawback is that Stimuloton is not cheap, but the package lasts for a month.
Before starting to take this drug, you should consult your doctor!
Umka
https://www.woman.ru/health/medley7/thread/4017827/1/#m25689054
I took it, normally, only while taking it I got the feeling that you were somewhere far from problems, and a strange state))) Iridescent and in general, as if I had drunk, only my consciousness works perfectly. After I took it during the day, I suffered from insomnia for three days. But I don’t know if it affected the liver. Nothing hurt. The pill itself has an excellent effect, there is no anxiety, no worries, anxiety goes away. Feels like I took a happy pill)
I recommend!
Natalia
https://lekotzyvy.com/preparat/s/stimuloton/
Well, what can I say. Almost every person experiences depression in their life. Those who have encountered such manifestations as panic attacks will understand me. This is not a pleasant condition, it occurs suddenly and unexpectedly. And, of course, bringing a lot of discomfort. The antidepressant Stimuloton acts quite quickly, only one tablet per day is needed, and is not addictive. I can say that the effect after its use lasts for a long time even after its cancellation. In general, after 3 weeks of taking this drug, my feeling of groundless anxiety began to go away, the sudden anxiety almost disappeared, my sleep and emotional state improved. I can say that many of my friends also used this medicine and it also brought relief to them. So, I recommend on my own behalf and not only. There are a lot of side effects, I’ll say right away, but where they are not. It’s not a fact that all of them will appear in you.
It is a good treatment for postpartum depression.
Marina
https://lekotzyvy.com/preparat/s/stimuloton/
For me, Stimulon has become a faithful friend and a reliable helper in dealing with depression, which for some reason worsened for me in the spring of last year. At that moment I didn’t want to do absolutely anything, I was indifferent to everything. In general, I turned to a psychotherapist for help, who prescribed Stimulon to me. I will say that before this the doctor prescribed me other antidepressants, which even were much more expensive, but they were of no use. I took one tablet in the morning. Very quickly my condition returned to normal.
I wanted to live again, not to give up, plus I was in a cheerful mood, and I also felt a sense of inner comfort.
Vera Solopova
https://lekotzyvy.com/preparat/s/stimuloton/
One of the mid-priced drugs of its kind for the treatment of depressive conditions. I had to buy Stimuloton for a loved one during another attack of depression. It was dispensed at the pharmacy without any problems with a doctor's prescription. There are medicines in almost every more or less large retail outlet. I don’t know how things stand with analogues, but the price, of course, is high - more than 1000 rubles for 30 tablets. As for whether it is effective or not, I can say that there is still help. This is not some kind of suggestion, the drug really helps a person cope with his illness and returns him to normal life. But it works on the principle of a cumulative effect - you need a course, you can’t get away with just one pill or a pack.
Alyona
https://lekotzyvy.com/preparat/s/stimuloton/
This was not the first time I had depression, I was treated with different things. Stimuloton seemed suspicious to me because the price is low, I usually buy antidepressants for 1,500 rubles. I expected a lot of side effects, but the doctor assured me that it was worth a try. There are 30 tablets in total, you take one per day, so you use it very sparingly. It is better to drink in the morning, because the drug provokes severe insomnia, especially at first. The effect came after about a week; before that there was no positive effect at all. The effect manifests itself in an emotional state, you just somehow relax inside, nervousness and irritability gradually go away. Sleep also normalizes, only after two or three weeks, but during the first week the situation was the opposite - the body seemed to get used to the drug, but for now it reacted with continuous insomnia. Then I suddenly began to sleep a lot, but after two weeks my sleep became normal—full, healthy.
A month of taking it was enough for me. to get rid of depression completely...
Stimuloton price, where to buy
You can buy it in pharmacies in Moscow and other cities. The price of Stimuloton depends on the dose of the drug and the number of tablets in the package. The cost of the drug 50 mg No. 10 ranges from 348 rubles. up to 419 rubles, and the drug 100 mg No. 28 - from 1285 rubles. up to 1648 rub.
- Online pharmacies in UkraineUkraine
Pharmacy24
- Stimuloton 50 mg No. 30 tablets ZAT FZ EGIS/VAT Pharmaceutical plant EGIS, Ugorshchina/Ugorshchina
234 UAH.order - Stimuloton 100 mg No. 28 tablets ZAT FZ Egis, Ugorshchina
383 UAH. order
